BHI Therapeutic Sciences, LLC is a healthcare research and consulting company, dedicated to the development of stem cell therapies.


Our scientific and medical teams are focused on IRB-approved protocols, designed to measure the safety and efficacy of intravenous, intra-articular, and intrathecal stem cell treatments. Our comprehensive stem cell protocols employ well-targeted combinations of autologous bone marrow stem cells, autologous adipose stem cells, and allogeneic human umbilical cord mesenchymal stem cells that treat various conditions such as spinal cord injury, traumatic brain injury, and chronic inflammation.


An American Institutional Review Board has approved our protocols and we are currently in talks with local partners in China, Germany, Slovakia, and Switzerland.


BHI Therapeutic Sciences, LLC was incorporated March 2015.


We foresee a future in which stem cell therapies are preferred over many surgical, pharmacological, and rehabilitative medical services. Our focus is to bring high-quality advanced stem cell therapies within reach of a wider audience in a safe and ethical manner.


We are currently looking for investors. Please contact us here for more detailed information about the company.